Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 9%

Bulls say

Arvinas is a company with an innovative approach to treat debilitating and life-threatening diseases by targeting specific disease-causing proteins. The company has a strong pipeline with promising product candidates in both oncology and neuroscience, backed by partnerships with large pharmaceutical companies. With the successful completion of the VEPPANU deal, the company is now well-funded and has a clear path to achieving key milestones that could drive significant value for investors. Furthermore, recent positive data from its product ARV-102 in PD patients and upcoming data from its PSP program demonstrate the potential of its protein degradation platform. The company is well-positioned for potential growth and success in the biotech industry.

Bears say

Arvinas is facing potential competition in the protein degradation space with multiple other companies also working on similar technologies and treatments. The company currently has a limited pipeline and lacks a diverse portfolio, which could hinder its long-term growth potential. Additionally, its financials show a steady decrease in net income and an increase in operating expenses, raising concerns about its ability to sustain its operations in the future.

Arvinas Inc (ARVN) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 11 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.